Skip to Content

Perjeta Approval History

  • FDA approved: Yes (First approved June 8th, 2012)
  • Brand name: Perjeta
  • Generic name: pertuzumab
  • Dosage form: Injection
  • Company: Genentech
  • Treatment for: Breast Cancer

Perjeta (pertuzumab) is a humanized monoclonal antibody indicated for the treatment of HER2-positive breast cancer.

Development History and FDA Approval Process for Perjeta

Dec 20, 2017Approval FDA Approves Genentech’s Perjeta (Pertuzumab) for Adjuvant Treatment of Specific Type of Early Breast Cancer
Jun  5, 2017APHINITY Study Shows Genentech’s Perjeta-Based Regimen Reduced the Risk of Invasive Cancer Returning Compared to Herceptin and Chemotherapy in HER2-Positive Early Breast Cancer
Sep 30, 2013Approval FDA Approves Perjeta for Neoadjuvant Breast Cancer Treatment
Jun  8, 2012Approval FDA Approves Perjeta (pertuzumab) for People With HER2-Positive Metastatic Breast Cancer
Feb  7, 2012FDA Grants Genentech's Pertuzumab Priority Review for Previously Untreated HER2-Positive Metastatic Breast Cancer

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.